BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Avrukibart readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Avrukibart\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07449702-1812@assetmemo.bio
DTSTAMP:20261121T004114Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Avrukibart: Phase 2 readout est. (NCT07449702)
DESCRIPTION:Avrukibart\, phase 2\, Psoriasis.\nStudy: An Open-Label Extensi
 on Study of ORKA-001 in Participants With Plaque Psoriasis\nEstimated prim
 ary completion: May 2030. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/avrukibart#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07449702
URL:https://assetmemo.bio/drug/avrukibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
